IO Frontiers World 2019


John Connolly

Dr John Connolly

Chief Scientific Officer, Tessa Therapeutics

Dr. Connolly has 20 years of research experience in immunotherapy and is a recognized world leader in the field of deep immune monitoring. In addition to his role as the Chief Scientific Officer of Tessa, Dr. Connolly is also a Senior Principal Investigator and Director for Translational Immunology at the Institute of Molecular and Cell Biology under the Agency for Science, Technology and Research in Singapore. He is an Adjunct Associate Professor of Immunology at Baylor University and the National University of Singapore. Previously, Dr. Connolly was the Director of Research Initiatives at the Baylor Research Institute and a member of the faculty at the Baylor Institute for Immunology Research, a fully translational center dedicated to rationally designed vaccines against cancer and infectious diseases. He was involved in the development of immunotherapeutic preclinical models and clinical trials for Glioblastoma multiforme, melanoma and breast cancer. Dr. Connolly received his Ph.D. in Immunology from Dartmouth Medical School and is also on the editorial and review panels for numerous scientific journals. He has published more than 75 papers and chapters in peer-reviewed journals.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy